Trial Profile

Metro-PD1: a Phase I/II Trial Evaluating Anti-PD1 (Nivolumab) in Combination With Metronomic Chemotherapy in Children and Teenagers With Refractory/Relapsing Solid Tumors

Status: Active, no longer recruiting

Phase of Trial: Phase I/II

Latest Information Update: 24 Jun 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Capecitabine (Primary) ; Cyclophosphamide (Primary) ; Nivolumab (Primary) ; Vinblastine (Primary)
Indications Ependymoma; Ewing's sarcoma; Glioma; Lymphoma; Neuroblastoma; Rhabdomyosarcoma; Solid tumours
Focus Adverse reactions; Therapeutic Use
Acronyms Metro-PD1

Most Recent Events

24 Jun 2024 This trial has been Discontinued in Belgium, according to European Clinical Trials Database record.
03 May 2024 Status changed from suspended to active, no longer recruiting.
28 Feb 2024 Status changed from recruiting to suspended for interim analysis.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com